A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma

Status
Active
Cancer Type
Pancreatic Cancer
Trial Phase
Phase II
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT01472198
Protocol IDs
GS-US-324-0101 (primary)
Study Sponsor
Gilead Sciences

Summary

This randomized study compares the efficacy of GS-6624 versus placebo in combination with Gemcitabine in subjects with Pancreatic cancer.

Objectives

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma